Melinta Therapeutics, Inc. announced that its Board of Directors has appointed Christine Ann Miller as Chief Executive Officer, effective August 3, 2020. Ms. Miller is a global pharmaceutical veteran with more than 20 years of experience in life sciences. Most recently, Ms. Miller led the global and U.S. product portfolio for Sandoz, where she was accountable for transitioning the portfolio toward rapid-growth and higher-margin segments, such as complex generics and value-added medicines, while continuing to build the branded generics business. With the appointment of Ms. Miller and effective as of the commencement date of Ms. Miller’s employment, Jennifer Sanfilippo will step down from her role as Interim Chief Executive Officer.